Sea Change In Drug Assistance Programs May Be On Horizon

By Clint Hermes and Jennifer Michael (July 15, 2021, 5:17 PM EDT) -- High-cost biologics continue to command a growing share of the overall pharmaceutical market, placing an increasing financial strain on both patients and payors.[1]

Some pharmaceutical manufacturers and patient advocacy groups believe that the government should promote patient access to expensive therapies by allowing manufacturers to subsidize federal health care beneficiaries' cost-sharing obligations for the manufacturers' own drugs.

Others, including government agencies, are concerned that allowing manufacturers to subsidize the cost-sharing obligations for their own drugs may threaten the sustainability of Medicare and other federal health care programs. Both may be right, leaving the industry at a crossroads.

This article provides a...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!